{"id":"lac-triple-therapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL391426","moleculeType":"Small molecule","molecularWeight":"1380.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LAC triple therapy typically refers to a combination regimen used in oncology that may include chemotherapy, targeted therapy, or immunotherapy components. The specific composition and mechanism depend on the cancer type being treated. As a phase 3 investigational regimen from the National Cancer Center Korea, it is designed to improve efficacy over standard treatments through synergistic effects of its component drugs.","oneSentence":"LAC triple therapy combines three agents to enhance anti-tumor immune response and inhibit cancer cell proliferation through complementary mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:18:09.783Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT01678027","phase":"PHASE3","title":"Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2004-11","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Family Members","enrollment":1838},{"nctId":"NCT03498456","phase":"PHASE3","title":"Triple Therapy With Tegoprazan in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-06-28","conditions":"Helicobacter Pylori Infection","enrollment":284}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PPI-Clarithromycin containing triple therapy"],"phase":"phase_3","status":"active","brandName":"LAC triple therapy","genericName":"LAC triple therapy","companyName":"National Cancer Center, Korea","companyId":"national-cancer-center-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tegoprazan, in combination with amoxicillin and clarithromycin, is a triple therapy used to treat Helicobacter Pylori infection. This therapy is also being studied for its potential efficacy in gastric cancer, although the exact mechanism of action is a small molecule modality.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}